Simplex Trading’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-23,096
| Closed | -$1.26M | – | 8601 |
|
|
2025
Q3 | $1.25M | Buy |
+23,096
| New | +$1.32M | ﹤0.01% | 2820 |
|
|
2025
Q2 | – | Sell |
-4,834
| Closed | -$285K | – | 8658 |
|
|
2025
Q1 | $341K | Sell |
4,834
-43,409
| -90% | -$2.92M | ﹤0.01% | 3796 |
|
|
2024
Q4 | $3.17M | Buy |
+48,243
| New | +$3.23M | ﹤0.01% | 1805 |
|
|
2024
Q3 | – | Sell |
-8,351
| Closed | -$698K | – | 8509 |
|
|
2024
Q2 | $687K | Sell |
8,351
-9,287
| -53% | -$773K | ﹤0.01% | 3319 |
|
|
2024
Q1 | $1.54M | Sell |
17,638
-10,865
| -38% | -$973K | ﹤0.01% | 2669 |
|
|
2023
Q4 | $2.75M | Buy |
+28,503
| New | +$2.52M | ﹤0.01% | 2091 |
|
|
2023
Q2 | – | Sell |
-9,652
| Closed | -$908K | – | 8987 |
|
|
2023
Q1 | $938K | Buy |
+9,652
| New | +$1M | ﹤0.01% | 2655 |
|
|
2022
Q4 | – | Sell |
-8,825
| Closed | -$828K | – | 9234 |
|
|
2022
Q3 | $748K | Sell |
8,825
-2,397
| -21% | -$213K | ﹤0.01% | 2991 |
|
|
2022
Q2 | $929K | Buy |
11,222
+280
| +3% | +$22.3K | ﹤0.01% | 2703 |
|
|
2022
Q1 | $843K | Sell |
10,942
-15,523
| -59% | -$1.3M | ﹤0.01% | 3117 |
|
|
2021
Q4 | $2.34M | Buy |
26,465
+14,151
| +115% | +$1.17M | ﹤0.01% | 1876 |
|
|
2021
Q3 | $1.03M | Sell |
12,314
-3,614
| -23% | -$285K | ﹤0.01% | 3015 |
|
|
2021
Q2 | $1.33M | Sell |
15,928
-6,596
| -29% | -$523K | ﹤0.01% | 2721 |
|
|
2021
Q1 | $1.7M | Buy |
22,524
+22,424
| +22,424% | +$1.83M | ﹤0.01% | 1796 |
|
|
2020
Q4 | $8K | Sell |
100
-35,899
| -100% | -$2.85M | ﹤0.01% | 7507 |
|
|
2020
Q3 | $2.74M | Buy |
35,999
+10,749
| +43% | +$1.09M | ﹤0.01% | 1281 |
|
|
2020
Q2 | $3.11M | Buy |
25,250
+4,773
| +23% | +$474K | 0.01% | 1168 |
|
|
2020
Q1 | $1.73M | Buy |
20,477
+5,414
| +36% | +$466K | ﹤0.01% | 1394 |
|
|
2019
Q4 | $1.27M | Buy |
15,063
+7,688
| +104% | +$581K | ﹤0.01% | 1869 |
|
|
2019
Q3 | $497K | Buy |
+7,375
| New | +$568K | ﹤0.01% | 2635 |
|
|
2019
Q2 | – | Sell |
-5,051
| Closed | -$432K | – | 7096 |
|
|
2019
Q1 | $448K | Buy |
5,051
+381
| +8% | +$35.3K | ﹤0.01% | 2769 |
|
|
2018
Q4 | $397K | Sell |
4,670
-4,553
| -49% | -$433K | ﹤0.01% | 2442 |
|
|
2018
Q3 | $894K | Buy |
9,223
+2,175
| +31% | +$217K | ﹤0.01% | 2013 |
|
|
2018
Q2 | $663K | Buy |
7,048
+883
| +14% | +$77.3K | ﹤0.01% | 2181 |
|
|
2018
Q1 | $499K | Sell |
6,165
-5,317
| -46% | -$456K | 0.02% | 716 |
|
|
2017
Q4 | $1.02M | Buy |
+11,482
| New | +$998K | 0.04% | 394 |
|
|
2017
Q3 | – | Sell |
-2,778
| Closed | -$245K | – | 5898 |
|
|
2017
Q2 | $252K | Sell |
2,778
-93
| -3% | -$8.46K | 0.01% | 1054 |
|
|
2017
Q1 | $252K | Sell |
2,871
-12,771
| -82% | -$1.14M | 0.01% | 1070 |
|
|
2016
Q4 | $1.29M | Sell |
15,642
-2,489
| -14% | -$214K | 0.08% | 222 |
|
|
2016
Q3 | $1.68M | Buy |
18,131
+1,528
| +9% | +$144K | 0.11% | 160 |
|
|
2016
Q2 | $1.29M | Buy |
16,603
+16,011
| +2,705% | +$1.36M | 0.09% | 219 |
|
|
2016
Q1 | $48K | Buy |
+592
| New | +$48.2K | ﹤0.01% | 1980 |
|
|
2015
Q4 | – | Sell |
-233
| Closed | -$24.3K | – | 5405 |
|
|
2015
Q3 | $24K | Buy |
+233
| New | +$31.1K | ﹤0.01% | 2611 |
|
Other funds holding BMRN
VPC
Simplex Trading's BMRN Position: Q4 2025 in Review
Simplex Trading sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 23,096 shares — an estimated $1.26M sold.
Simplex Trading first reported a position in BMRN in Q3 2015 and held it in 33 quarters. The position peaked at $3.17M in Q4 2024. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.
- Simplex Trading reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Simplex Trading sold 23,096 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $1.26M.
- Simplex Trading first reported a position in BioMarin Pharmaceuticals in Q3 2015 and held it in 33 quarters.
- Simplex Trading's BioMarin Pharmaceuticals position peaked at $3.17M in Q4 2024.
- 539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.
Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.